We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-16.77%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$140M
AUM Growth
-$33.4M
Cap. Flow
+$24.5K
Cap. Flow %
0.02%
Top 10 Hldgs %
90.94%
Holding
43
New
3
Increased
9
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$327K
2
AXDX
Accelerate Diagnostics
AXDX
+$282K
3
CELG
Celgene Corp
CELG
+$278K
4
PACB icon
Pacific Biosciences
PACB
+$266K
5
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$164K

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$508K
2
PTCT icon
PTC Therapeutics
PTCT
+$483K
3
GILD icon
Gilead Sciences
GILD
+$387K
4
CERS icon
Cerus
CERS
+$313K
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$221K

Sector Composition

Rank Sector Weight
1 Healthcare 91.79%
2 Energy 3.24%
3 Consumer Staples 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$78M 55.59%
779,051
+2,700
+0.3% +$278K
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$31.3M 22.29%
217,580
+2,000
+0.9% +$282K
VRML
3
DELISTED
Vermillion, Inc.
VRML
$4M 2.85%
2,717,514
– –
YTEN
4
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$3.87M 2.76%
236
– –
EQT icon
5
EQT Corp
EQT
$31B
$2.85M 2.03%
77,705
– –
BIOL
6
DELISTED
Biolase, Inc.
BIOL
$1.69M 1.2%
103
– –
CFRX
7
DELISTED
ContraFect Corporation
CFRX
$1.61M 1.15%
594
– –
MASI
8
DELISTED
Masimo
MASI
$1.53M 1.09%
36,600
– –
COLL icon
9
Collegium Pharmaceutical
COLL
$1.17B
$1.39M 0.99%
76,768
+18,000
+31% +$327K
HNSN
10
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$1.38M 0.98%
528,142
-1
-0% -$2
NBIX icon
11
Neurocrine Biosciences
NBIX
$17.2B
$997K 0.71%
25,200
+2,000
+9% +$79.4K
MDVN
12
DELISTED
MEDIVATION, INC.
MDVN
$863K 0.62%
18,760
-14,000
-43% -$508K
OVV icon
13
Ovintiv
OVV
$16.2B
$806K 0.57%
26,460
– –
MRK icon
14
Merck
MRK
$315B
$794K 0.57%
15,720
– –
OMED
15
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$715K 0.51%
70,689
+12,000
+20% +$141K
QDEL icon
16
QuidelOrtho
QDEL
$1.19B
$673K 0.48%
38,975
– –
OXFD
17
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$558K 0.4%
56,303
+16,000
+40% +$164K
ARAY icon
18
Accuray
ARAY
$30.8M
$551K 0.39%
95,300
– –
QTNT
19
DELISTED
Quotient Limited Ordinary Shares
QTNT
$512K 0.37%
1,455
– –
WMGI
20
DELISTED
Wright Medical Group Inc
WMGI
$498K 0.36%
30,000
– –
CTRA
21
DELISTED
Coterra Energy
CTRA
$477K 0.34%
21,000
– –
SIEN
22
DELISTED
Sientra, Inc.
SIEN
$433K 0.31%
6,330
– –
NXTM
23
DELISTED
NxStage Medical Inc.
NXTM
$423K 0.3%
28,200
+2,500
+10% +$41.9K
PXD
24
DELISTED
Pioneer Natural Resource Co.
PXD
$422K 0.3%
3,000
– –
CORT icon
25
Corcept Therapeutics
CORT
$9.72B
$374K 0.27%
80,000
– –
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Birchview Capital held 43 positions worth $140M, down 19% from $174M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Birchview Capital's Q1 2016 filing shows 3 new, 9 increased, 4 reduced and 3 closed positions. Its largest new stake was Pacific Biosciences: 27,000 shares worth $230K. The largest sale was MEDIVATION, INC., an estimated $508K.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2016 buy was Pacific Biosciences: 27,000 shares worth $230K.
  • Birchview Capital added most to Collegium Pharmaceutical in Q1 2016, an estimated $327K increase.
  • Birchview Capital's biggest Q1 2016 reduction was MEDIVATION, INC., cutting an estimated $508K.
  • Birchview Capital fully exited PTC Therapeutics in Q1 2016, selling an estimated $483K.
  • Birchview Capital's ten largest holdings make up 91% of its $140M portfolio in Q1 2016.
  • Birchview Capital opened 3 new positions and closed 3 in Q1 2016.
  • Birchview Capital's portfolio value fell 19% quarter-over-quarter to $140M.

Based on Birchview Capital's 13F filing for Q1 2016, filed 28 Apr 2016.